VIVORYON THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.453 EUR | -3.62% |
|
-8.48% | -94.43% |
Business Summary
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Number of employees: 15
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Samir Shah
BRD | Director/Board Member | 63 | 21-12-31 |
| Director/Board Member | 56 | 18-08-30 | |
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Claudia Riedl
BRD | Director/Board Member | 54 | 21-12-31 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 25,961,892 | 17,348,972 ( 66.82 %) | 0 | 66.82 % |
Company contact information
Sector
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.453
EUR
Average target price
41.57
EUR
Spread / Average Target
+9,075.87%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.43% | 12.6M | |
| -1.42% | 41.52B | |
| +42.15% | 39.9B | |
| +1.97% | 38.83B | |
| -14.19% | 26.05B | |
| +1.82% | 23.78B | |
| -24.55% | 18.26B | |
| -4.07% | 11.65B | |
| +21.36% | 11.53B | |
| +8.20% | 11.2B |
- Stock Market
- Equities
- VVY Stock
- Company Vivoryon Therapeutics N.V.
